Short description
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from rare kidney diseases.
Description
Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Paris and Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France.
Last funding
Cannot Access
Sign in for full access
Total funding
$$3123123
Sign in for full access
Location
Paris, Ile-de-France, France, Europe
Founded on
January 1, 2007
Exited on
December 6, 2017
Went public on
December 6, 2017
Stock symbol
ADVIC
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$7890 - 12340
Sign in for full access
Investors
Blurry Noaccess, Uh Ohhhh, Noaccessforu, Nopepepe, Nopepepe, Absolutely Noaccess, Cannot Access, Noaccess, Absolutely Noaccess, Nopepepe
Sign in for full access
Founders
Caroline Roussel-Maupetit, Luc Andre Granier